Efficacy of Edaravone, a Free Radical Scavenger, for the Treatment of Acute Lacunar Infarction

Abstract

The effect of edaravone as an inhibitor of ischemic brain damage in addition to routine treatment was retrospectively examined in 70 patients with lacunar infarction who were admitted within 24 hours of symptom onset. Clinical status was assessed using the National Institutes of Health Stroke Scale (NIHSS). The modified Rankin Scale (MRS) was used to assess clinical outcomes at 3 months after onset, with a good outcome defined as MRS score Ã2. Risk factors were also evaluated, including evidence of hypertension, diabetes mellitus, hyperlipidemia, coronary heart disease, and a history of smoking longer than 2 months. The probability of a good outcome and independence at 3 months was assessed by backward stepwise logistic regression analysis based on the maximum likelihood ratio. Administration of edaravone yielded an odds ratio with multivariate adjustment of 6.49 (95% confidence interval, 1.35 to 50.32; p º 0.05) for a good outcome at 3 months. Higher baseline NIHSS score and higher age also adversely affected the outcome at 3 months (p º 0.005). Administration of edaravone improves the outcome of patients with lacunar infarction.

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

“…A previous study on 70 patients of acute lacunar infarction had similarly shown that administration of this drug improves the functional outcome in these patients [64].…”

Efficacy of the Free Radical Scavenger, Edaravone, for Motor Palsy of Acute Lacunar Infarction

“…The free radical scavenger, edaravone, is the first neuroprotective agent approved by the Japanese Ministry of Health and Welfare for clinical use. Although a randomized, placebo-controlled, double-blind study conducted at multiple centers in Japan showed the efficacy of edaravone in acute cerebral infarction (3), the clinical trials are few (4)(5)(6) (9). Although there were no significant differences in NIHSS on admission and NIHSS at discharge in the two groups, NIHSS on admission was slightly larger and NIHSS at discharge was smaller in the edaravone group.…”

Administration of Free Radical Scavenger Edaravone Associated With Higher Frequency of Hemorrhagic Transformation in Patients With Cardiogenic Embolism

“…We previously reported that edaravone use improved the outcome of the patients with lacunar infarction. 14) We think that edaravone is also useful for the treatment of patients with cardiogenic embolism. In addition, edaravone is expected to extend the therapeutic time window for thrombolytic therapy by protecting endothelial cells and neurons.…”

“…1) Edaravone was apparently efficacious in patients with acute ischemic stroke, 7,14) and protected vascular endothelial cells and neurons during acute brain ischemia. 22) EPC-K1, another free radical scavenger, combined with heparin dramatically reduced heparin-induced hemor- Fig.…”